Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | GLA | P06280 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | BTK | Q06187 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | SERPINE1 | P05121 | 3/20 | 0.41 |
| ▸ | GABRP | O00591 | 2/20 | 0.40 |
| ▸ | GABRD | O14764 | 2/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.40 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.40 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3044265 | 0.86 | KDM4E (0.71) | KDM4EALDH1A1GAAHSD17B10SERPINE1 | |
| SCHEMBL11536873 | 0.83 | KDM4E (0.63) | KDM4EALDH1A1GLAGAAHSD17B10 | |
| SCHEMBL1309023 | 0.82 | ALDH1A1 (0.50) | KDM4EALDH1A1GLAGAAMEN1 | |
| SCHEMBL28534851 | 0.81 | USP2 (0.55) | KDM4EALDH1A1GAAHPGDRAB9A | |
| SCHEMBL30661117 | 0.80 | MAPT (0.64) | ALDH1A1GAASMN1; SMN2SERPINE1MAPT | |
| SCHEMBL19253255 | 0.80 | MAPT (0.64) | ALDH1A1GAASMN1; SMN2SERPINE1MAPT | |
| SCHEMBL19268087 | 0.79 | TP53 (0.54) | KDM4EALDH1A1HSD17B10KMT2ASMN1; SMN2 | |
| SCHEMBL19268075 | 0.79 | GABRP (0.63) | KDM4EALDH1A1HSD17B10RAB9ASMN1; SMN2 | |
| SCHEMBL8766311 | 0.78 | MEN1 (0.59) | ALDH1A1GAAMEN1KMT2ARAB9A | |
| SCHEMBL11445926 | 0.77 | ALDH1A1 (0.56) | KDM4EALDH1A1GLAGAAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8053441-B2 | Pyrazolylquinazolinones as potassium channel openers | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-11-08 | — | — | US | disclosed |
| US-8053441-B2 | Pyrazolylquinazolinones as potassium channel openers | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-11-08 | — | — | US | disclosed |
| US-8053441-B2 | Pyrazolylquinazolinones as potassium channel openers | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-11-08 | — | — | US | disclosed |
| CN-101400672-A | Pyrazolylquinazolinones as potassium channel openers | JANSSEN PHARMACEUTICA NV (BE) | 2009-04-01 | — | — | CN | disclosed |
| EP-1989197-A1 | PYRAZOLYLQUINAZOLINONES AS POTASSIUM CHANNEL OPENERS | Janssen Pharmaceutica, N.V. (BE) | 2008-11-12 | — | — | EP | disclosed |
| WO-2007098386-A1 | PYRAZOLYLQUINAZOLINONES AS POTASSIUM CHANNEL OPENERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-08-30 | — | — | WO | disclosed |
| WO-2007098386-A1 | PYRAZOLYLQUINAZOLINONES AS POTASSIUM CHANNEL OPENERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-08-30 | — | — | WO | disclosed |
| US-20070197566-A1 | NOVEL PYRAZOLYLQUINAZOLINONES AS POTASSIUM CHANNEL OPENERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-08-23 | — | — | US | disclosed |
| US-20070197566-A1 | NOVEL PYRAZOLYLQUINAZOLINONES AS POTASSIUM CHANNEL OPENERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-08-23 | — | — | US | disclosed |
| US-20070197566-A1 | NOVEL PYRAZOLYLQUINAZOLINONES AS POTASSIUM CHANNEL OPENERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197566-A1 | NOVEL PYRAZOLYLQUINAZOLINONES AS POTASSIUM CHANNEL OPENERS | KCNJ2, KCNQ1, KCNN3 | KDM4E 1752/4885ALDH1A1 1760/4885GLA 4488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.